{"id":"ticagrelor-maintenance-dose","safety":{"commonSideEffects":[{"rate":"4-6","effect":"Bleeding"},{"rate":"3-5","effect":"Bradycardia"},{"rate":"13-14","effect":"Dyspnea"},{"rate":"2-3","effect":"Ventricular pauses"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, inhibiting platelet activation and aggregation. This prevents clot formation in patients at high risk of cardiovascular events. The maintenance dose is used after an initial loading dose to sustain antiplatelet effects in acute coronary syndrome and other thrombotic conditions.","oneSentence":"Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:43.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis"},{"name":"Secondary prevention of atherothrombotic events in patients with prior myocardial infarction"}]},"trialDetails":[{"nctId":"NCT06543082","phase":"PHASE4","title":"MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study","status":"RECRUITING","sponsor":"CHA University","startDate":"2024-08-05","conditions":"Acute Coronary Syndrome","enrollment":490},{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT06591377","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-10","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT06318481","phase":"PHASE3","title":"TADCLOT- a Double Blind Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-02-19","conditions":"Stent Thrombosis, Myocardial Infarction, Acute","enrollment":2200},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT02733341","phase":"PHASE4","title":"The Effect of IV Cangrelor and Oral Ticagrelor Study","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2016-07-21","conditions":"Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO)","enrollment":100},{"nctId":"NCT03551964","phase":"PHASE4","title":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2018-08-01","conditions":"Acute Myocardial Infarction, Cardiogenic Shock","enrollment":605},{"nctId":"NCT06759272","phase":"PHASE4","title":"Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients","status":"NOT_YET_RECRUITING","sponsor":"Nur Hafizah Annezah binti Utuh","startDate":"2025-02","conditions":"Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD","enrollment":120},{"nctId":"NCT06584812","phase":"PHASE1","title":"Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects","status":"COMPLETED","sponsor":"Tianjin Institute of Pharmaceutical Research Co., Ltd","startDate":"2024-09-09","conditions":"Acute Coronary Syndrome, Ischemic Stroke","enrollment":14},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT06591390","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-02-09","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02016170","phase":"NA","title":"Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-03","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":82},{"nctId":"NCT06254391","phase":"PHASE2","title":"Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2023-07-03","conditions":"Myocardial Infarction, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT05978791","phase":"","title":"Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-10-11","conditions":"Arterial Thrombosis","enrollment":24},{"nctId":"NCT05831462","phase":"PHASE1, PHASE2","title":"De-escalation of Ticagrelor in Post PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Ticagrelor","enrollment":400},{"nctId":"NCT04718025","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2022-02-07","conditions":"STEMI, NSTEMI, Unstable Angina","enrollment":4500},{"nctId":"NCT03251859","phase":"PHASE3","title":"Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2017-08-11","conditions":"Myocardial Infarction","enrollment":52},{"nctId":"NCT05779059","phase":"PHASE3","title":"Prasugrel Or Ticagrelor De-escalation in NSTE-ACS","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2023-04-01","conditions":"Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina","enrollment":50},{"nctId":"NCT01944800","phase":"PHASE4","title":"Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2013-09-15","conditions":"Acute Coronary Syndrome (ACS)","enrollment":4018},{"nctId":"NCT02677545","phase":"PHASE2","title":"Ticagrelor Versus Clopidogrel in Carotid Artery Stenting","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-12","conditions":"Carotid Artery Stenosis","enrollment":210},{"nctId":"NCT05210595","phase":"PHASE4","title":"Optimal Dosage of Ticagrelor in Korean Patients With AMI","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2022-01-01","conditions":"Acute Myocardial Infarction, Ticagrelor","enrollment":120},{"nctId":"NCT03437044","phase":"PHASE4","title":"Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":40},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT03533153","phase":"PHASE1, PHASE2","title":"Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-03-01","conditions":"Myocardial Infarction","enrollment":90},{"nctId":"NCT02931045","phase":"PHASE4","title":"Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2017-12-30","conditions":"Myocardial Infarction","enrollment":60},{"nctId":"NCT03354429","phase":"PHASE3","title":"THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-22","conditions":"Acute Ischaemic Stroke, Transient Ischaemic Attack","enrollment":11016},{"nctId":"NCT02617290","phase":"PHASE3","title":"Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-09","conditions":"Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction","enrollment":1900},{"nctId":"NCT03489863","phase":"PHASE4","title":"Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-05-30","conditions":"Coronary Artery Disease","enrollment":14},{"nctId":"NCT03989557","phase":"PHASE4","title":"Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms","status":"COMPLETED","sponsor":"Beijing Neurosurgical Institute","startDate":"2019-07-01","conditions":"Unruptured Intracranial Aneurysm, Stents, Antiplatelet Drugs","enrollment":314},{"nctId":"NCT04116931","phase":"PHASE4","title":"OPTImal Management of Antithrombotic Agents: OPTIMA-5","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-06-22","conditions":"Acute Coronary Syndrome (ACS)","enrollment":80},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT04206176","phase":"PHASE1, PHASE2","title":"The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease","status":"COMPLETED","sponsor":"The University of The West Indies","startDate":"2019-10-01","conditions":"Platelet Dysfunction Due to Drugs","enrollment":25},{"nctId":"NCT03454841","phase":"","title":"Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2018-02-26","conditions":"Acute Myocardial Infarction","enrollment":73},{"nctId":"NCT02376283","phase":"PHASE4","title":"P3AMI Antiplatelet Trial","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2015-03-09","conditions":"Heart Attack","enrollment":87},{"nctId":"NCT02086903","phase":"PHASE3","title":"Clopidogrel And Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2014-02","conditions":"Pharmacodynamics","enrollment":12},{"nctId":"NCT04060914","phase":"PHASE4","title":"LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-08-30","conditions":"Antiplatelet Therapy, Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":225},{"nctId":"NCT02071212","phase":"PHASE2","title":"Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.","status":"COMPLETED","sponsor":"Hellenic Cardiovascular Research Society","startDate":"2014-02","conditions":"Coronary Artery Disease","enrollment":120},{"nctId":"NCT03111420","phase":"NA","title":"Study of AggreGuide A-100 (ADP) Assay","status":"COMPLETED","sponsor":"Aggredyne, Inc.","startDate":"2017-01-09","conditions":"Risk Factor, Cardiovascular, Platelet Dysfunction Due to Drugs","enrollment":280},{"nctId":"NCT02327624","phase":"PHASE4","title":"STEEL Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-06","conditions":"Coronary Artery Disease","enrollment":180},{"nctId":"NCT01587651","phase":"PHASE4","title":"Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-03","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT02164864","phase":"PHASE3","title":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-22","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2725},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT03184805","phase":"NA","title":"STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2017-06-23","conditions":"Coronary Artery Disease","enrollment":140},{"nctId":"NCT02422888","phase":"PHASE4","title":"Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":110},{"nctId":"NCT02519608","phase":"PHASE2","title":"ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2015-09","conditions":"Coronary Artery Disease, Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT02048085","phase":"PHASE4","title":"Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis","status":"WITHDRAWN","sponsor":"Medical Center of South Arkansas","startDate":"2014-01-02","conditions":"Acute ST Segment Elevation Myocardial Infarction, Acute Coronary Syndrome","enrollment":""},{"nctId":"NCT02201394","phase":"PHASE4","title":"Reversing Ticagrelor's Effects With Fresh Platelets","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-07","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT02075125","phase":"PHASE3","title":"Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction","status":"TERMINATED","sponsor":"Dong-A University","startDate":"2014-01","conditions":"ST-Segment Elevation Myocardial Infarction","enrollment":39},{"nctId":"NCT02808767","phase":"PHASE4","title":"Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2013-01","conditions":"Myocardial Infarction, Angioplasty, Balloon, Coronary, Platelet Aggregation Inhibitors","enrollment":1226},{"nctId":"NCT03005704","phase":"NA","title":"Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2017-01","conditions":"Ticagrelor, Aspirin, Platelet Dysfunction Due to Drugs","enrollment":10},{"nctId":"NCT01957540","phase":"PHASE4","title":"Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Patras","startDate":"2014-06","conditions":"Coronary Artery Disease, Endothelial Function","enrollment":22},{"nctId":"NCT02224534","phase":"PHASE4","title":"Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2014-10","conditions":"ST Elevation Myocardial Infarction","enrollment":326},{"nctId":"NCT01962428","phase":"PHASE4","title":"Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI","status":"COMPLETED","sponsor":"General Hospital of Chinese Armed Police Forces","startDate":"2014-06","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":250},{"nctId":"NCT01852214","phase":"NA","title":"Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-02","conditions":"Diabetes Mellitus, Coronary Artery Disease","enrollment":50},{"nctId":"NCT02580149","phase":"PHASE4","title":"The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment","status":"COMPLETED","sponsor":"Michael Wolzt, Prof. MD","startDate":"2015-10","conditions":"Ischemia","enrollment":24},{"nctId":"NCT02052635","phase":"PHASE4","title":"Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Non-ST Elevation Acute Coronary Syndrome","enrollment":34},{"nctId":"NCT02457130","phase":"PHASE4","title":"Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)","status":"UNKNOWN","sponsor":"Spanish Society of Cardiology","startDate":"2015-04","conditions":"Coronary Artery Disease, Diabetes Mellitus. Type 2","enrollment":30},{"nctId":"NCT01950416","phase":"PHASE4","title":"Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis","status":"COMPLETED","sponsor":"University of Patras","startDate":"2013-03","conditions":"ST Elevation Myocardial Infarction, Fibrinolysis, P2Y12 Inhibitor","enrollment":56},{"nctId":"NCT01731041","phase":"NA","title":"Impact of Ticagrelor Re-load on Pharmacodynamic Profiles","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":60},{"nctId":"NCT01852175","phase":"NA","title":"Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2012-01","conditions":"Coronary Artery Disease","enrollment":110},{"nctId":"NCT01864005","phase":"PHASE4","title":"A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-05","conditions":"Non-ST or ST Elevation Acute Coronary Syndromes","enrollment":60},{"nctId":"NCT02402491","phase":"PHASE4","title":"Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-01","conditions":"Percutaneous Coronary Intervention","enrollment":1000},{"nctId":"NCT02394145","phase":"PHASE3","title":"Genotype and Platelet Reactivity in Patients on Hemodialysis","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2009-09","conditions":"Chronic Kidney Disease","enrollment":20},{"nctId":"NCT02201667","phase":"PHASE4","title":"Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2014-08","conditions":"Acute Coronary Syndrome","enrollment":444},{"nctId":"NCT02163954","phase":"PHASE3","title":"ONSET and OFFSET of Ticagrelor in ESRD","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2013-01","conditions":"Chronic Kidney Disease","enrollment":16},{"nctId":"NCT02120092","phase":"PHASE2","title":"The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-10","conditions":"Acute Coronary Syndrome","enrollment":89},{"nctId":"NCT02012140","phase":"PHASE4","title":"Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2014-01","conditions":"Cardiovascular Disease, Stable Angina, Myocardial Infarction","enrollment":200},{"nctId":"NCT01456364","phase":"PHASE4","title":"Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2011-09","conditions":"Coronary Heart Disease","enrollment":70},{"nctId":"NCT01660373","phase":"PHASE3","title":"Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Pusan National University Yangsan Hospital","startDate":"2012-08","conditions":"Non-ST Segment Elevation Acute Coronary Syndrome","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ticagrelor","Brilinta"],"phase":"marketed","status":"active","brandName":"Ticagrelor maintenance dose","genericName":"Ticagrelor maintenance dose","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}